CommentCGRP as a new target in prevention and treatment of migraine
References (11)
- et al.
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
Lancet Neurol
(2014) Evidence of the involvement of CGRP in migraine and cluster headache: a physiological perspective
- et al.
Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers
Neurology
(2014) - et al.
CGRP receptor antagonism and migraine therapy
Curr Protein Pept Sci
(2013) - et al.
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
N Engl J Med
(2004)
Cited by (24)
The Itch–Scratch Cycle: A Neuroimmune Perspective
2018, Trends in ImmunologyCitation Excerpt :It is tempting to postulate that behavioral responses and sensory dysfunction in other tissues such as the meninges (migraine headaches), cochlear and vestibular apparatus (tinnitus and vertigo), airway (asthma and cough), gut (irritable bowel syndrome), and bladder (interstitial cystitis) may involve a similar neuroimmune interplay as in the itch–scratch cycle. The breadth of clinical indications for itch-modulating drugs support this notion: dupilumab (anti-IL-4rα) is also being used to treat asthma [97,98] and CGRP antagonists are now indicated for migraine headaches [99] (Table 1). Similarly, SP receptor (NK-1R) antagonists are in development for chronic pruritus and PN [100], as well as Sézary syndrome, a cutaneous T cell lymphoma that is highly pruritic [101].
Antinociception of the spirocyclopiperazinium salt compound LXM-15 via activating α7 nAChR and M4 mAChR and inhibiting CaMKIIα/cAMP/CREB/CGRP signalling pathway in mice
2018, Regulatory Toxicology and PharmacologyCitation Excerpt :Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide and a member of the calcitonin family of peptides (Malon et al., 2011), is one of the key molecular events in the nociceptive transmission and excitability of postsynaptic neurons (Oku et al., 1987). Previous studies have reported that intrathecal injection of CGRP produces a significant hyperalgesia to mechanical noxious stimuli in rats, and CGRP receptor antagonists such as telcagepant are effective in treating migraine symptoms (Diener, 2014; Ho et al., 2010; Lee et al., 2013). The present study showed that formalin injection led to an upregulation of CGRP in the DRG and spinal cord.
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
2017, The Lancet NeurologyCitation Excerpt :Small-molecule CGRP receptor antagonists, also known as gepants, have previously shown efficacy for acute treatment of migraine, although concerns with liver toxicity from telcagepant halted clinical development.26 Studies of monoclonal antibodies as preventive therapy for migraine have shown potential with respect to efficacy and safety.14,27–31 Erenumab is the only fully human monoclonal antibody in clinical development that potently binds in a competitive and reversible manner (Ki 0·02 nM) to the CGRP receptor with greater selectivity than to other human calcitonin family receptors (eg, calcitonin, amylin, and adrenomedullin).32
Headache and facial pain
2016, Medicine (United Kingdom)Citation Excerpt :New options for migraine treatment, in particular calcitonin gene-related peptide antibodies, are in late-stage clinical trials.5
New therapeutic approaches for the prevention and treatment of migraine
2015, The Lancet NeurologyCitation Excerpt :There seems little doubt that blockade of the CGRP pathway is an effective preventive strategy of migraine, and the results of ongoing studies are eagerly awaited. However, there are also several caveats associated with this therapeutic strategy:70 none of the new monoclonal antibodies has been tested long enough to exclude adverse events on long-term use. The frequency and biological consequence of the generation of auto-antibodies against these therapeutic antibodies are still unknown.
Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons
2022, Neurological Sciences